ALPS Medical Breakthroughs ETF Rating → Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years (From Banyan Hill Publishing) (Ad) Free SBIO Stock Alerts $32.16 +0.63 (+2.00%) (As of 04/26/2024 ET) Add Compare Share Share RatingsStock AnalysisChartHoldingsOwnershipRatingsStock AnalysisChartHoldingsOwnershipRatings ALPS Medical Breakthroughs ETF Aggregate Rating and Price Target (2024)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.SBIO Aggregate RatingModerate Buy2.83Holdings in SBIO have an aggregate rating of Moderate Buy based on 388 analyst ratings issued in the past year covering 50 companies (82.8% of the portfolio).SBIO Aggregate Price Target$51.5060.13% UpsideHigh Prediction$70.67Average Prediction$51.50Low Prediction$35.50Holdings in SBIO have an aggregate price target of $51.50 and a range of $35.50 to $70.67 covering 50 companies (82.8% of the portfolio).SBIO Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy24 Buy rating(s)Moderate Buy22 Moderate Buy rating(s)Hold4 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by ALPS Medical Breakthroughs ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 50 SBIO Holdings Export to ExcelWeightIn ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings4.84%CERECerevel Therapeutics$42.47+1.0%0 of 5 stars2.20$41.40 -2.5%10Upcoming EarningsShort Interest ↓4.72%VKTXViking Therapeutics$74.31+7.9%5 of 5 stars3.00$112.25 51.1%10Earnings ReportAnalyst ReportAnalyst Revision4.45%PCVXVaxcyte$60.72+1.1%2 of 5 stars3.00$78.50 29.3%4Insider SellingNews Coverage3.91%RVMDRevolution Medicines$35.96+1.8%4 of 5 stars3.10$41.20 14.6%10Positive News2.68%ALPNAlpine Immune Sciences$64.56-0.1%2 of 5 stars2.27$50.33 -22.0%11Short Interest ↓2.65%ALKSAlkermes$24.68+1.0%5 of 5 stars2.50$35.38 43.3%10Upcoming EarningsShort Interest ↓2.37%CRNXCrinetics Pharmaceuticals$42.12-0.4%4 of 5 stars2.91$54.00 28.2%11Upcoming EarningsShort Interest ↑2.15%AXSMAxsome Therapeutics$71.71+0.3%4 of 5 stars2.92$119.67 66.9%122.06%XENEXenon Pharmaceuticals$40.50+1.0%3 of 5 stars3.00$59.44 46.8%9Positive News2.06%SWTXSpringWorks Therapeutics$45.53+3.0%3 of 5 stars3.00$68.00 49.4%6Upcoming EarningsNews Coverage2.03%IDYAIDEAYA Biosciences$39.94+3.4%3 of 5 stars3.00$46.60 16.7%122.01%ACLXArcellx$51.92+1.1%3 of 5 stars3.00$75.64 45.7%12Short Interest ↑1.87%IMCRImmunocore$58.46+0.8%3 of 5 stars2.85$81.50 39.4%13Analyst ReportShort Interest ↓News Coverage1.82%ACADACADIA Pharmaceuticals$16.71+2.5%4 of 5 stars2.80$32.13 92.3%15Analyst Revision1.79%SMMTSummit Therapeutics$3.86+8.7%1 of 5 stars3.00$8.00 107.3%1Upcoming EarningsGap Up1.73%MLTXMoonLake Immunotherapeutics$42.49+0.6%3 of 5 stars2.75$74.46 75.2%12Analyst ReportPositive News1.70%VERAVera Therapeutics$39.65+2.5%1 of 5 stars3.00$32.29 -18.6%81.69%DNLIDenali Therapeutics$15.43+3.1%3 of 5 stars3.00$41.22 167.2%8News Coverage1.67%CLDXCelldex Therapeutics$36.30+0.1%0 of 5 stars2.80$66.00 81.8%5Upcoming Earnings1.62%RYTMRhythm Pharmaceuticals$38.28+0.3%2 of 5 stars3.00$47.20 23.3%5Analyst Report1.61%ARVNArvinas$32.37+2.4%3 of 5 stars2.88$59.73 84.5%16Upcoming EarningsNews Coverage1.58%MRUSMerus$45.04+0.2%2 of 5 stars3.00$56.33 25.1%11Upcoming EarningsAnalyst RevisionNews Coverage1.56%CORTCorcept Therapeutics$22.80+2.7%5 of 5 stars3.00$39.30 72.4%4Upcoming EarningsAnalyst ReportGap Up1.52%NTLAIntellia Therapeutics$20.76+3.7%4 of 5 stars2.69$67.00 222.7%13Upcoming EarningsAnalyst ReportNews Coverage1.49%VCELVericel$46.05+1.3%0 of 5 stars3.00$46.40 0.8%6News Coverage1.41%KROSKeros Therapeutics$57.86+6.8%2 of 5 stars3.00$86.00 48.6%7Upcoming Earnings1.36%NMRANeumora Therapeutics$9.15+1.0%1 of 5 stars2.86$22.57 146.7%7News Coverage1.31%GERNGeron$3.79+6.5%3 of 5 stars3.00$5.33 40.7%3Upcoming EarningsShort Interest ↑News Coverage1.30%GLPGGalapagos$28.76+0.5%0 of 5 stars2.00$34.50 20.0%5Upcoming EarningsShort Interest ↑1.28%RNAAvidity Biosciences$24.36+2.2%1 of 5 stars3.00$36.33 49.2%61.20%SNDXSyndax Pharmaceuticals$21.06+2.4%4 of 5 stars2.90$34.42 63.4%10Analyst Report1.18%CPRXCatalyst Pharmaceuticals$14.89+1.4%5 of 5 stars3.00$26.43 77.5%5Analyst RevisionNews Coverage1.09%AGIOAgios Pharmaceuticals$31.49-0.6%1 of 5 stars2.50$33.50 6.4%4Upcoming Earnings1.05%INBXInhibrx$34.06-0.1%1 of 5 stars2.00$27.00 -20.7%21.02%PTGXProtagonist Therapeutics$25.15+2.0%1 of 5 stars3.00$36.00 43.1%4Upcoming Earnings1.00%RCUSArcus Biosciences$15.55+5.6%3 of 5 stars2.88$41.25 165.3%8Short Interest ↓0.98%KURAKura Oncology$19.65+3.4%4 of 5 stars2.88$28.28 43.9%8Upcoming Earnings0.97%EWTXEdgewise Therapeutics$16.17+1.4%2 of 5 stars3.00$31.20 92.9%5Gap Up0.96%MORFMorphic$28.07+0.3%4 of 5 stars2.67$51.50 83.5%6News CoveragePositive News0.94%ZLABZai Lab$15.91+1.1%2 of 5 stars3.00$64.22 303.7%5Analyst RevisionGap Up0.91%TARSTarsus Pharmaceuticals$32.04-0.5%3 of 5 stars2.88$48.38 51.0%8News CoveragePositive News0.87%FDMT4D Molecular Therapeutics$23.25-1.2%3 of 5 stars3.00$44.22 90.2%100.83%VRNAVerona Pharma$15.47+1.0%2 of 5 stars3.00$33.60 117.2%4News Coverage0.80%DCPHDeciphera Pharmaceuticals$14.65+3.3%4 of 5 stars2.80$23.00 57.0%5Upcoming EarningsShort Interest ↓News CoveragePositive News0.80%IRWDIronwood Pharmaceuticals$7.82-3.2%4 of 5 stars3.00$19.80 153.2%5Upcoming Earnings0.80%XNCRXencor$19.98+3.9%4 of 5 stars2.89$36.00 80.2%9Positive News0.79%VIRVir Biotechnology$8.23+7.9%2 of 5 stars2.57$34.38 317.7%7Upcoming EarningsNews Coverage0.79%PRTAProthena$20.87+1.5%2 of 5 stars2.71$68.14 226.5%7Upcoming EarningsNews Coverage0.78%DAWNDay One Biopharmaceuticals$14.92+12.9%3 of 5 stars2.86$39.33 163.6%7Analyst ReportAnalyst RevisionNews CoverageHigh Trading Volume0.78%AKROAkero Therapeutics$19.74+4.3%3 of 5 stars2.86$37.71 91.1%7 This page (NYSEARCA:SBIO) was last updated on 4/28/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressWhy Big Pharma is Investing Billions in This BiotechBehind the MarketsJeff Bezos Just Humiliated Elon MuskInvestorPlaceThe only accurate crypto trading system I know …Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ALPS Medical Breakthroughs ETF Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
